CARTESIAN THERAPEUTICS INC (RNAC) Stock News

USA - Nasdaq - NASDAQ:RNAC - US8162123025 - Common Stock

7.9 USD

+1.18 (+17.56%)

Last: 12/9/2025, 8:27:36 PM

7.68 USD

-0.22 (-2.78%)

After Hours: 12/9/2025, 8:27:36 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

RNAC Latest News, Press Relases and Analysis

All

Press Releases

26 days ago - By: Benzinga

Cartesian Pauses Lupus And Multiple Myeloma Studies As It Shifts Development Focus

26 days ago - By: Benzinga - Mentions: AMAT NVDA GAP LOW ...

Nvidia To Rally Around 18%? Here Are 10 Top Analyst Forecasts For Friday

a month ago - By: Cartesian Therapeutics, Inc.

Cartesian Therapeutics Announces New Employment Inducement Grants

2 months ago - By: Cartesian Therapeutics, Inc.

Cartesian Therapeutics Announces New Employment Inducement Grant

4 months ago - By: The Motley Fool

Cartesian (RNAC) Q2 Revenue Drops 99%

3 months ago - By: Cartesian Therapeutics, Inc.

Cartesian Therapeutics to Participate in Upcoming Investor Conferences

4 months ago - By: Cartesian Therapeutics, Inc.

Cartesian Therapeutics Announces New Employment Inducement Grants

6 months ago - By: Cartesian Therapeutics, Inc.

Cartesian Therapeutics Announces New Employment Inducement Grants

6 months ago - By: Cartesian Therapeutics, Inc.

Cartesian Therapeutics Announces First Participant Enrolled in the Phase 3 AURORA Trial of Descartes-08 in Patients with Myasthenia Gravis

7 months ago - By: Cartesian Therapeutics, Inc.

Cartesian Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

7 months ago - By: Zacks Investment Research - Mentions: SRPT

Sarepta Therapeutics (SRPT) Reports Q1 Loss, Tops Revenue Estimates

7 months ago - By: Yahoo Finance - Mentions: DHI CMG

Why Cartesian Therapeutics, Inc. (RNAC) is Among the Best Small Cap Stocks to Buy with the Biggest Upside Potential

7 months ago - By: Cartesian Therapeutics, Inc.

Cartesian Therapeutics Announces New Employment Inducement Grants

8 months ago - By: Cartesian Therapeutics, Inc.

Cartesian Therapeutics’ Descartes-08 Observed to Provide Deep and Sustained Benefits Through Month 12 After a Single Course of Therapy in Phase 2b Myasthenia Gravis Trial

8 months ago - By: Cartesian Therapeutics, Inc.

Cartesian Therapeutics Announces New Employment Inducement Grants

8 months ago - By: Cartesian Therapeutics, Inc.

Cartesian Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference

9 months ago - By: Cartesian Therapeutics, Inc.

Cartesian Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update

9 months ago - By: Cartesian Therapeutics, Inc.

Cartesian Therapeutics Announces New Employment Inducement Grant

10 months ago - By: Cartesian Therapeutics, Inc.

Cartesian Therapeutics to Participate in Upcoming Investor Conferences

10 months ago - By: Cartesian Therapeutics, Inc.

Cartesian Therapeutics Announces New Employment Inducement Grants

11 months ago - By: Cartesian Therapeutics, Inc.

Cartesian Therapeutics Announces FDA Special Protocol Assessment Agreement for Phase 3 AURORA Trial of Descartes-08 in Myasthenia Gravis

a year ago - By: Cartesian Therapeutics, Inc.

Cartesian Therapeutics Announces New Employment Inducement Grants

a year ago - By: Cartesian Therapeutics, Inc.

Cartesian Therapeutics Announces New Employment Inducement Grants

a year ago - By: Cartesian Therapeutics, Inc.

Cartesian Therapeutics Announces Positive Updated Results from Phase 2b Trial of Descartes-08 in Participants with Myasthenia Gravis and Outlines Design of Planned Phase 3 Trial

a year ago - By: Cartesian Therapeutics, Inc.

Cartesian Therapeutics to Present Updated Data from Phase 2b Trial of Descartes-08 in Patients with Myasthenia Gravis at the 2nd Annual Cell Therapy for Autoimmune Disease Summit

a year ago - By: Cartesian Therapeutics, Inc.

Cartesian Therapeutics Announces New Employment Inducement Grants